机构:[1]State Key Laboratory of Biotherapy and Cancer Center/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.四川大学华西医院[2]Laboratory of Human Disease and Immunotherapies, West China Hospital, Sichuan University, Chengdu 610041, China.四川大学华西医院[3]Suzhou Zelgen Biopharmaceuticals Co., Ltd., Kunshan, Jiangsu 215301, China.[4]Institute of Life Science, Luoyang Normal University, Luoyang, Henan 471934, China.
Caseinolytic protease P (ClpP) is considered as a promising target for the treatment of Staphylococcus aureus infections. In an unbiased screen of 2632 molecules, a peptidomimetic boronate, MLN9708, was found to be a potent suppressor of SaClpP function. A time-saving and cost-efficient strategy integrating in silico position scanning, multistep miniaturized synthesis, and bioactivity testing was deployed for optimization of this hit compound and led to fast exploration of structure-activity relationships. Five of 150 compounds from the miniaturized synthesis exhibited improved inhibitory activity. Compound 43Hf was the most active inhibitor and showed reversible covalent binding to SaClpP while did not destabilize the tetradecameric structure of SaClpP. The crystal structure of 43Hf-SaClpP complex provided mechanistic insight into the covalent binding mode of peptidomimetic boronate and SaClpP. Furthermore, 43Hf could bind endogenous ClpP in S. aureus cells and exhibited significant efficacy in attenuating S. aureus virulence in vitro and in vivo.
基金:
The research was funded by National Mega-project for
Innovative Drugs (2019ZX09721001-001-001), National
Natural Science Foundation of China (nos. 81973368,
81670008, 81871615), National Key Research and Development Plan (no. SQ2016YFJC040104).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2020]版:
大类|1 区医学
小类|1 区药物化学
最新[2025]版:
大类|1 区医学
小类|1 区药物化学
第一作者:
第一作者机构:[1]State Key Laboratory of Biotherapy and Cancer Center/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.
共同第一作者:
通讯作者:
通讯机构:[1]State Key Laboratory of Biotherapy and Cancer Center/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.[*1]State Key Laboratory of Biotherapy and Cancer Center/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China
推荐引用方式(GB/T 7714):
Ju Yuan,He Lihui,Zhou Yuanzheng,et al.Discovery of Novel Peptidomimetic Boronate ClpP Inhibitors with Noncanonical Enzyme Mechanism as Potent Virulence Blockers in Vitro and in Vivo.[J].Journal of medicinal chemistry.2020,63(6):3104-3119.doi:10.1021/acs.jmedchem.9b01746.
APA:
Ju Yuan,He Lihui,Zhou Yuanzheng,Yang Tao,Sun Ke...&Luo Youfu.(2020).Discovery of Novel Peptidomimetic Boronate ClpP Inhibitors with Noncanonical Enzyme Mechanism as Potent Virulence Blockers in Vitro and in Vivo..Journal of medicinal chemistry,63,(6)
MLA:
Ju Yuan,et al."Discovery of Novel Peptidomimetic Boronate ClpP Inhibitors with Noncanonical Enzyme Mechanism as Potent Virulence Blockers in Vitro and in Vivo.".Journal of medicinal chemistry 63..6(2020):3104-3119